Journal
PARASITOLOGY RESEARCH
Volume 111, Issue 6, Pages 2473-2477Publisher
SPRINGER
DOI: 10.1007/s00436-012-3019-2
Keywords
-
Categories
Funding
- RI-INBRE from the National Center for Research Resources (NCRR), NIH [2P20RR016457-10, 2P20RR016457-11]
- NOAA [NA04OAR4600193]
- NIH, NCRR [P20-RR016457]
Ask authors/readers for more resources
Entamoeba histolytica infects 50 million people per year, causing 100,000 deaths worldwide. The primary treatment for amoebiasis is metronidazole. However, increased pathogen resistance combined with the drug's toxic side effects encourages a search for alternative therapeutic agents. Secondary metabolites from marine bacteria are a promising resource for antiprotozoan drug discovery. In this study, extracts from a collection of marine-derived actinomycetes were screened for antiamoebic properties, and the activities of antibiotics echinomycin A and tirandamycin A are shown. Both antibiotics inhibited the in vitro growth of a E. histolytica laboratory strain (HM-1:IMSS) and a clinical isolate (Colombia, Col) at 30- to 60-mu M concentrations. EIC50 (estimated inhibitory concentration) values were comparable for both antibiotics (44.3-46.3 mu M) against the E. histolytica clinical isolate.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available